CRIS Current Research Information System

GARAJOVA, INGRID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.321
NA - Nord America 3.097
EU - Europa 2.145
AF - Africa 169
SA - Sud America 136
OC - Oceania 8
Totale 8.876
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.058
VN - Vietnam 1.018
SG - Singapore 903
CN - Cina 746
IT - Italia 495
GB - Regno Unito 474
DE - Germania 248
SE - Svezia 229
HK - Hong Kong 212
IN - India 130
FR - Francia 123
KR - Corea 106
RU - Federazione Russa 105
BR - Brasile 91
IE - Irlanda 75
FI - Finlandia 74
CH - Svizzera 73
NL - Olanda 72
JP - Giappone 64
ZA - Sudafrica 48
UA - Ucraina 37
CI - Costa d'Avorio 36
EE - Estonia 34
TG - Togo 34
SC - Seychelles 26
CA - Canada 24
BG - Bulgaria 19
PH - Filippine 19
BE - Belgio 18
JO - Giordania 18
ID - Indonesia 14
PL - Polonia 14
TR - Turchia 14
TH - Thailandia 13
AR - Argentina 12
AT - Austria 12
GR - Grecia 11
NG - Nigeria 11
EC - Ecuador 10
MX - Messico 10
IQ - Iraq 9
PK - Pakistan 9
TW - Taiwan 9
BD - Bangladesh 8
ES - Italia 7
SA - Arabia Saudita 7
VE - Venezuela 7
IR - Iran 6
AU - Australia 5
CL - Cile 5
CO - Colombia 5
PT - Portogallo 5
RO - Romania 5
NI - Nicaragua 4
BH - Bahrain 3
EG - Egitto 3
HR - Croazia 3
LT - Lituania 3
PE - Perù 3
PS - Palestinian Territory 3
CZ - Repubblica Ceca 2
DZ - Algeria 2
KE - Kenya 2
LB - Libano 2
MA - Marocco 2
MN - Mongolia 2
MY - Malesia 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BO - Bolivia 1
BW - Botswana 1
DJ - Gibuti 1
ET - Etiopia 1
FJ - Figi 1
HT - Haiti 1
HU - Ungheria 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
TV - Tuvalu 1
Totale 8.876
Salva come PNG Salva come JPEG
Città #
Singapore 637
Southend 410
Ashburn 302
Fairfield 283
Ho Chi Minh City 248
Hanoi 236
Chandler 223
Hong Kong 195
Hefei 185
San Jose 166
Santa Clara 150
Dallas 140
Wilmington 137
Houston 136
Woodbridge 125
Seattle 120
Ann Arbor 118
Dong Ket 98
Princeton 97
Cambridge 96
Seoul 93
Bologna 82
Beijing 80
Dublin 75
Boardman 70
Helsinki 69
Bern 66
Tokyo 53
Los Angeles 51
Lauterbourg 50
Nanjing 48
Rome 42
Westminster 42
Berlin 41
Padova 38
Abidjan 36
Da Nang 35
Lomé 34
New York 30
Frankfurt am Main 29
Haiphong 29
Milan 28
Buffalo 25
Medford 21
Bengaluru 19
Saint Petersburg 19
Sofia 19
Turin 19
Amman 18
Changsha 17
Shenyang 17
Guangzhou 16
Redondo Beach 16
Brussels 15
Council Bluffs 15
San Diego 14
Jinan 13
Orem 13
Ravenna 13
Tianjin 13
Toronto 13
Hebei 12
London 12
Nuremberg 12
Dearborn 11
Phủ Lý 11
São Paulo 11
Jacksonville 10
Shanghai 10
Warsaw 10
Amsterdam 9
Nha Trang 9
Quận Ba 9
Rimini 9
Tongling 9
Vũng Tàu 9
Bến Tre 8
Falls Church 8
Hangzhou 8
Hải Dương 8
Olalla 8
Quận Bình Thạnh 8
Zhengzhou 8
Abeokuta 7
Bắc Giang 7
Can Tho 7
Denver 7
Munich 7
Mülheim 7
Parma 7
Phoenix 7
Torino 7
Wuhan 7
Xi'an 7
Atlanta 6
Bangkok 6
Biên Hòa 6
Chicago 6
Falkenstein 6
Florence 6
Totale 5.860
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 451
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 307
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 296
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 251
[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma] 250
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 245
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 238
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 225
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 209
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 208
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer 207
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 207
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 203
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 202
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 197
Antiapoptotic genes are overexpressed in the group of patients with locally advanced rectal adenocarcinomas who do not respond to neoadjuvant chemoradiotherapy 194
Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis 192
Epigenetic and epitranscriptomic changes in colorectal cancer: diagnostic, prognostic, and treatment implications 188
In Reply 188
Should patients on levothyroxine therapy be screened for pancreatic cancer? 180
Second-line chemotherapy in patients with biliary tract cancer. 178
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 176
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 171
[Gene expression profiling in prediction of tumor response to neoadjuvant concomitant chemoradiotherapy in patients with locally advanced rectal carcinoma: pilot study] 171
Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma 167
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 166
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 164
MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy 162
The follow-up issues: from the necessity to the opportunity 151
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 150
c-Met as a Target for Personalized Therapy 148
Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. 147
Second-line chemotherapy in biliary tract cancer patients. 147
Feasibility of triplets (5-FU, oxaliplatin and irinotecan based) in front and subsequent lines of metastatic colorectal cancer patients. 143
Circulating micrornas as dynamic biomarkers of disease progression during folfirinox therapy in unresectable pancreatic ductal adenocarcinoma (pdac) 139
D43Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer 137
380 POSTER Association of miR21, miR31, miR143, miR145 and let-7a-1 levels with histopathologic features of colorectal cancer 133
Altered expression of heat shock protein 110 (HSP110), hypoxia up- regulated 1 (HYOU1) and translationally controled tumor protein (TCTP) during colorectal cancer progression 131
Oxaliplatin in pre-treated patients: Maybe not the match point? 125
Significant overexpression of Hsp110 gene during colorectal cancer progression 124
Neoadjuvant treatment in rectal cancer: actual status. 122
Prognostic significance of tumor-infiltrating cytotoxic T-cells in colorectal cancer 118
The role of microRNAs in resistance to current pancreatic cancer treatment: Translational studies and basic protocols for extraction and PCR analysis 116
Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer 114
Occupational exposure to asbestos: a putative unknown risk factor for intrahepatic cholangiocarcinoma. 110
D44The overall survival of patients affected by metastatic colorectal cancer before and after “monoclonal antibodies era”: a monocentric retrospective study 108
L27MiR-21 expression as prognostic biomarker in extrahepatic but not intrahepatic radically resected cholangiocarcinomas 106
MicroRNA profiling of primary pulmonary enteric adenocarcinoma shows similarity with lung cancer and pancreatic cancer 105
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development 102
Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second-line clinical trials 93
1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study 78
Synchronous and metachronous colorectal liver metastases: Impact of primary tumor location on patterns of recurrence and survival after hepatic resection 65
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 58
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 38
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 33
Totale 9.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.005
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.005
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021238 0 0 0 0 0 0 0 0 0 32 21 185
2021/2022808 83 36 35 46 84 46 25 50 45 32 163 163
2022/20231.037 114 169 76 101 68 66 24 83 140 38 66 92
2023/2024269 39 40 9 32 11 51 9 17 11 14 22 14
2024/20251.419 54 215 118 73 215 55 107 79 44 81 108 270
2025/20263.347 357 439 380 217 301 176 489 133 657 198 0 0
Totale 9.034